Rapport Therapeutics Q1 net loss $24.1M; RAP-219 epilepsy trial on track for Q3 2025 data

Rapport Therapeutics, Inc.

2025-Q1 EPS reported -$0.68

Net loss $24.1M in Q1 2025 vs $22.7M prior year; R&D expenses rose to $19.6M from $12.5M.
Cash & short-term investments $285.4M at Mar 31, 2025 (down from $305.3M Dec 31, 2024); runway through end of 2026.
RAP-219 Phase 2a refractory focal epilepsy topline results expected Q3 2025.
RAP-219 Phase 2a bipolar mania trial to start Q3 2025; topline data expected H1 2027.
Dr. Jeffrey Sevigny appointed CMO; Investor & Analyst Day scheduled June 2, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.